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Abstract
Background
Variation in the carboxylesterase 1 gene (CES1) may contribute to the efficacy of ACEIs.
Accordingly, we examined the impact of CES1 variants on plasma angiotensin II (ATII)/
angiotensin I (ATI) ratio in patients with congestive heart failure (CHF) that underwent
ACEI dose titrations. Five of these variants have previously been associated with drug
response or increased CES1 expression, i.e., CES1 copy number variation, the variant of
the duplicated CES1 gene with high transcriptional activity, rs71647871, rs2244613, and
rs3815583. Additionally, nine variants, representatives of CES1Var, and three other CES1
variants were examined.
Methods
Patients with CHF, and clinical indication for ACEIs were categorized according to their
CES1 genotype. Differences in mean plasma ATII/ATI ratios between genotype groups
after ACEI dose titration, expressed as the least square mean (LSM) with 95% confidence
intervals (CIs), were assessed by analysis of variance.
Results
A total of 200 patients were recruited and 127 patients (63.5%) completed the study. The
mean duration of the CHF drug dose titration was 6.2 (SD 3.6) months. After ACEI dose
titration, there was no difference in mean plasma ATII/ATI ratios between subjects with the
investigated CES1 variants, and only one previously unexplored variation (rs2302722)
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qualified for further assessment. In the fully adjusted analysis of effects of rs2302722 on
plasma ATII/ATI ratios, the difference in mean ATII/ATI ratio between the GG genotype
and the minor allele carriers (GT and TT) was not significant, with a relative difference in
LSMs of 0.67 (95% CI 0.43–1.07; P = 0.10). Results of analyses that only included enala-
pril-treated patients remained non-significant after Bonferroni correction for multiple parallel
comparisons (difference in LSM 0.60 [95% CI 0.37–0.98], P = 0.045).
Conclusion
These findings indicate that the included single variants of CES1 do not significantly influ-
ence plasma ATII/ATI ratios in CHF patients treated with ACEIs and are unlikely to be pri-
mary determinants of ACEI efficacy.
Introduction
Activation of the renin-angiotensin-aldosterone system (RAAS) plays a pivotal role in cardio-
vascular disease and treatment with angiotensin-converting enzyme inhibitors (ACEIs), which
inhibit the hydrolytic conversion of angiotensin I (ATI) to angiotensin II (ATII), forms an
important part of the treatment for congestive heart failure (CHF), hypertension, and ischemic
heart disease. ACEI treatment, however, is associated with substantial variability in efficacy,
which cannot solely be explained by individual differences in clinical characteristics [1–8].
Although genetic diversity may contribute to such variability there is as yet very limited evi-
dence available on this clinically important subject [9].
Most ACEIs are ester prodrugs, which are hydrolyzed to their active metabolites by hepatic
carboxylesterase 1 (CES1) [10–12]. The activity of CES1 has been associated with marked indi-
vidual variability and variants in the CES1 gene (CES1) as well as pharmacological CES1 inhibi-
tion have been shown to influence the CES1 hydrolytic capacity, and hence the activation of
ACEIs [13–18]. The structure of CES1 is complex. For example, CES1 is subjected to duplica-
tion. The duplicated version of CES1 is designatedCES1A2, whileCES1A1 is the original gene
copy [19]. Duplication of CES1 has been associated with the pharmacokinetics of irinotecan in
a dosage-dependentmanner [20]. The haplotype of CES1A2with the ‘active promoter’, which
is characterized by having two Sp1 transcription factor binding sites, has been associated with a
higher transcriptional level of CES1 that may lead to increased CES1 activity [18, 19]. On the
other hand, a well-established non-synonymous missense single nucleotide polymorphism
(SNP), rs71647871 (Gly143Glu), in CES1A1 has been associated with decreasedCES1 activity
and reduced bioactivation of trandolapril [13]. In addition to ACEIs, CES1 is also important to
the metabolism of clopidogrel, the anticoagulant prodrug dabigatran exitelate, and the central
acting psychostimulant methylphenidate [21–23]. In this regard, rs2244613, which is located
in a CES1A1 intronic region, has been associated with decreased bioavailability of dabigatran,
the activated metabolite of dabigatran exitelate, and reduced bleeding in dabigatran etxitelate-
treated patients, and rs3815583 in the CES1A1 promoter, has been linked to appetite reduction
among ADHD patients treated with methylphenidate e [24, 25]. CES1A1 also harbors a set of
SNPs in its upstream part that are in strong LD with each other, including a SNP with a poten-
tial effect on the amount of enzyme produced, due to its localization in the Kozak sequence of
the gene. To our knowledge, there are no reports available on the relationship betweenCES1
variants and pharmacodynamic effects of ACEIs and it is notable that the plasma ATII/ATI
CES1 Gene Variants and ACEI Treatment
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ratio is closely correlated to circulating levels of active ACEI metabolites [26–29]. In this study
we therefore examined the influence of the above-mentioned genetic variations in CES1 on
the plasma ATII/ATI ratio in ACEI-treated patients with CHF including nine of the SNPs in
the upstream part of CES1A1, which form the so-calledCES1Var. In addition, three selected
CES1 variants that were not suspected to have a functional impact themselves were included as
potential markers of causal genetic variants.
Materials and Methods
Subjects
In the period 2012–2014 patients18 years of age with CHF of any cause and a left ventricular
ejection fraction45% who were referred to the CHF outpatient clinic at Gentofte University
Hospital, Copenhagen,Denmark, for initiation or dose titration of ACEIs and other CHF
drugs were recruited for the study. Patients were routinely followed by outpatient consultations
every second to fourth week until completion of CHF drug dose titration. Main exclusion crite-
ria were treatment with captopril or lisinopril that are not metabolized by CES1 [10], treatment
with angiotensin II type I receptor blockers, pregnancy, malignant disease, CHF requiring hos-
pitalization, and baseline serum creatinine150 mmol/l. At baseline blood samples (10 ml)
were collected in EDTA-containing tubes for CES1 genotyping. Patients were followed until
they had been titrated to maximal tolerable doses of ACEIs, beta-blockers, and aldosterone
antagonists, for at least two weeks or a maximum of 2 months [30]. On the day of study termi-
nation, blood samples (10 ml) were collected for determination of plasma ATI and ATII levels,
and the plasma ATII/ATI ratio was calculated. Blood samples were collected during day time
(9:00 AM–2:00 PM) in pre-chilled tubes containing EDTA and aprotinine, immediately centri-
fuged, and plasma stored at -20°C until analysis. The patients rested for 15–20 minutes in a sit-
ting position prior to blood sample collection and the time of the last preceding ACEI drug
ingestion was carefully recorded. Patients who stopped ACEI treatment during the follow up
periodwere excluded and the causes for ACEI discontinuation, e.g., adverse events or non-
compliance, were registered.
Plasma angiotensin analyses
The plasma concentrations of ATI and ATII were determined by radioimmunoassay as
describedpreviously [31, 32]. Specific anti-ATI and anti-ATII antibodies, i.e., Ab-3-20008939
and Ab-5–030682 raised in rabbits were used in final dilutions of at least 1:100.000. There was
<0.1% cross reactivity between these antibodies for ATI and ATII, but Ab-5–030682 cross-
reacts with shorter bioactive angiotensins [31]. In brief, plasma samples were acidified by 4%
acetic acid, extracted by use of C-18 Sep-Pak cartridges (Waters, Hedehusene, Denmark) and
dried overnight. After elution, samples and antibodies were incubated for 24 hours, and known
amounts of 125Iodine (I)-labeledATI and ATII were then added for another 24 hours of incu-
bation. Sediments of free antigen were obtained by adding a charcoal-plasma suspension fol-
lowed by centrifugation. Finally, the radioactivity of the supernatant representing 125I bound
antibodies was measured, the ATI and ATII concentrations were determined, and plasma ATI/
ATII ratio was calculated.
Genetic analyses
GenomicDNA was extracted from the EDTA-stabilized blood samples using theMaxwell1stru-
ment (Promega Corporation,Madison,WI, USA). Subsequently, we determined the total num-
ber of copies of CES1A1 and CES1A2 using a commercially available assay based on duplex real-
CES1 Gene Variants and ACEI Treatment
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time PCR (Thermo Fisher Scientific,Waltham, MAUSA). This assay targeted intron 11 (Taq-
Man1 copy number assay Hs00139541_cn) in CES1A1 and CES1A2. Since this region is identi-
cal in CES1A1 and CES1A2 the assay determined the number of copies of both of these gene
versions. Deletion of CES1A1 has not been reported. Hence, all individuals in our study were
assumed to harbor two CES1A1 copies. With this assumption, a copy number of three or four as
determined by the above assay signifiedpresence of one or two CES1A2 copies.
For samples lackingCES1A2 two overlapping long range PCRs were carried out allowing
for the amplification of all CES1A1 exons. The first of these long PCRs amplified a 12.5 kb frag-
ment of the gene containing its promoter and exon 1–5. The second long PCR amplified a 19.2
kb CES1A1 fragment containing exon 6–14. For samples with three or four copies, i.e. samples
harboringCES1A1 as well as CES1A2, the 12.5 kb fragment of CES1A1 as well as the corre-
sponding CES1A2 fragment with the approximately same size was amplified. The long PCR for
amplification of the CES1A1 fragment containing exon 6–14 is unable to distinguishCES1A1
from CES1A2 and was therefore not applicable for analysis of samples containing both of these
gene versions. The sequences of the forward and reverse primers for amplification of the 12.5
kb fragment of CES1A1were 5’-ACTATGGGGGGACGGAGTTCA-3’ and 5’-CCAGTCCT
GAATTCAGGTATTGTAAT CA-3’. The 12.5 kb fragment of CES1A2was amplified using the
same reverse primer and a forward primer with the sequence 5’- CAGGAGCTATTGAGA
GATGGAATCAT-3’. For amplification of the 19.2 kb fragment of CES1A1we used a forward
and reverse primer with the sequences 5’-CTGATTACAATACCT GAATTCAGGAC-3’ and
5’-GTATTTCTGCTCATTATGGT CACG-3’, respectively. The amplified fragments were sub-
jected to Sanger sequencing in order to determine the genotypes of the following CES1A SNPs:
rs3815583, rs12149373, rs12149371, rs12149322, rs12149370, rs12149368, rs111604615,
rs566557773, rs201577108, rs12149366, rs56278207, rs71647871, rs2302722, rs2244614, and
rs2244613. We also identified the CES1A2 variant with increased transcriptional activity, i.e.,
the haplotype carrying the ‘active promoter’ [18]. Our procedure was validated using a variety
of different approaches. Notably, we showed that the CES1A2 specific primers did not support
amplification of samples that did not harbor this gene variant as determined by the real time
PCR described above, and traces of CES1P1 (the CES1-related pseudogene) or other undesired
sequences were not detected in the Sanger chromatograms (not shown).
The single nucleotide variations rs12149368, rs12149373, rs12149371, rs12149322, rs12149370,
rs111604615, rs566557773, rs201577108, and rs12149366, which all are located in the 5’ UTR or
exon 1 of CES1A1, constitute a major haploblock. The variation rs12149368 resides at a position
immediately upstream to the initiation codon of CES1A1, thereby altering the Kozak sequence in
this gene. The variations rs111604615, rs201577108 and rs12149366 all cause an amino acid
change. Consequently, we hypothesized that the abovementionedmajor haploblock was associ-
ated with altered CES1 activity [33]. The single nucleotide variation rs56278207, which is located
in intron 1 of CES1A1, is in LDwith the variations in the major haploblock and served as an addi-
tional marker of this block. Similarly, rs2244614 of CES1A1, which is in linkage disequlibrium
with rs2244613, was included in the analysis. Finally, intronic rs2302722 was selected as another
marker since its genotype proportion was compatible with those expectedunderHardy-Weinberg
equilibrium (HWE) and theminor allele frequency (MAF) of this single nucleotide variation was
found to exceed 0.05.
Alignment of sequences and detection of genetic variants were done using Lasergene
(DNASTAR, Madison,WI, USA). For mapping we applied Geneious v7.1.5 (Biomatters, Auck-
land, New Zealand).CES1A1 sequences were aligned to Hg19 (GRh37.p13) and CES1A2
sequences were alignedwith AB119998.1. The CES1A2 variant with the “active promoter” was
identified based upon previously published sequence information [18]. Measures of pairwise
linkage disequilibrium (LD) expressed as r2 were calculated and visualized using Haploview
CES1 Gene Variants and ACEI Treatment
PLOS ONE | DOI:10.1371/journal.pone.0163341 September 23, 2016 4 / 18
v4.2 [34]. The LD blocks were identified using the confidence interval method implemented
in Haploview. The Chi-square test was used to examine whether genotype proportions corre-
sponded to those expected under Hardy-Weinberg equilibrium.
Statistics
One-way analyses of variance (ANOVA) were applied to model the differences between geno-
type groups in means for the plasma ATII/ATI ratio. Results from the ANOVA models values
were given as least square means (LSMs). To fit the assumption of a normally distributed out-
come variable, values of the plasma ATII/ATI ratio were transformed into a base 10 logarith-
mic scale before statistical assessment. Initially, all genetic variants were assessed in univariate
analyses. Only variants that produced a univariate significance level of P0.30 were further
investigated in multivariate ANOVA models adjusted for age, sex, height, blood pressure, treat-
ment with spironolactone or eplerenone, treatment with beta-blockers and, ultimately, also
adjusted for the timespan from last ACEI tablet ingestion until blood sample collection at the
day of study termination. The single nucleotide variants under examination were bi-allelic and
thus giving rise to three genotypes each. Hence, these variants were initially included as three-
level variables. By contrast, the CES1A2 haplotype with the ‘active promoter’ was exclusively
examined as a binary (active vs. inactive) variable [18]. In the adjusted models, the genetic vari-
ants with three genotypes were condensed into dichotomous variables, i.e., carriers or non-car-
riers of the minor allele, to increase the statistical power of the study. Sensitivity analyses were
done in a sub-group of enalapril-treated patients. The absence of interaction between variables
and the assumption of exposure group equality of the standard deviation were fulfilled if not
otherwise stated. Due to multiple testing, we used a Bonferroni-corrected significance level of
P0.01 (standard P-value of 0.05 divided by the number of independent analyses) for evalua-
tion of the association betweenCES1 variants and the outcome measure. SNPs located in a hap-
loblock are not independent and for such SNPs we therefore only corrected once. Variants
with low minor allele frequencies (MAFs) were excluded from the association analyses. We
used a Bonferroni-corrected significance level of P0.003 for the assessment of P values in the
Hardy Weinberg equilibrium (HWE) tests since these included all 15 examinedCES1 SNP
genotypes and the copy number variation. Analyses and data management were performed in
SAS version 9.3 (SAS Institute Inc. Cary, North Carolina).
Ethics
This study was approved by the Danish National Committee on Health Research Ethics (Pro-
tocol no.: H-4-2012-094) and the Danish data protection agency (I-suite no.: 01825 and identi-
fication no.: GEH-2012-032), respectively. All participants gave their written informed consent
before inclusion.
Results
Study population and CES1 genetics
A total of 200 patients with CHF were recruited for the study. Hereof, 50 (25%) patients were
excluded because they discontinued their ACEI treatment before the final CHF drug dose
titration was achieved, 9 (4.5%) failed to show up for scheduled appointments, 8 (4.0%) were
excluded due to severe comorbidity (liver cirrhosis [n=1] and cancer [n=4]) or potential ACEI
adverse effects (kidney failure [n=1], hyperkalemia [n=1], and symptomatic hypotension
[n=1]), and 6 (3.0%) patients died, leaving 127 (63.5%) subjects available for analysis. Of these
127 patients, 99 (78%) were treated with enalapril, 24 (19%) with ramipril, and 4 (3%) with
CES1 Gene Variants and ACEI Treatment
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trandolapril, respectively. The mean duration of the CHF drug dose titration periodwas 6.2
(SD 3.6) months. Other baseline characteristics of subjects in the total and analyzed study pop-
ulation are shown in Table 1. As shown in Fig 1, there was a time-dependent and inverse rela-
tionship between plasma ATI levels and the plasma ATII/ATI ratio (P for interaction = 0.026).
The distribution of CES1A2with 2 (n = 89), 3 (n = 34), and 4 (n = 4) CES1 copies, respectively,
were in HWE (P = 0.73). Allele frequencies of the CES1A1 variants are shown in Table 2.
Plasma levels of ATI and ATII, and the plasma ATII/ATI ratio, respectively, in subjects with
each of the CES1 variants are shown in Table 3. The single nucleotide variants at rs12149373,
rs12149322, rs111604615, rs566557773, rs201577108, rs12149366 were not in HWE
(P<0.003) and the frequencies of the minor allele at rs71647871 and the “active promoter” of
CES1A2were low (0.01 [n=2] and 0.03 [n=2], respectively) (Table 2). Accordingly, these three
variants were not considered for further statistical analysis. Similarly, data on the CES1A2
‘active promoter’ was not included in Table 2 as this haplotype was rare in our study popula-
tion. The reference alleles of rs56278207, rs2244613 and rs2244614 were not the major alleles
[35]. The majority of the investigated SNPs within CES1A1were highly correlated as evidenced
by high R2 values in the pairwise comparisons as shown in Fig 2. Data were missing for 41 indi-
viduals in the analyses of rs2302722, rs2244614, and rs2244613, respectively, which reflected
that the long PCR for amplification of exon 6–14 of CES1A1 is unable to discriminateCES1A1
from CES1A2 and therefore was not applicable for analysis of CES1A1 in individuals carrying
CES1A2 (Table 2).
Table 1. Baseline characteristics of the analyzed study population (n = 127).
Female (n, [%]) 30 (23.0)
Age (mean [SD] years) 68.50 (11.7)
Systolic BP (mmHg, mean [SD]) 125.31 (17.9)
Diastolic BP (mmHg, mean [SD]) 73.12 (11.3)
Height (cm, mean [SD]) 176.48 (9.0)
BMI (kg/m2, mean [SD]) 26.29 (4.6)
NYHA class (mean [SD]) 1.46 (0.6)
EF (mean [SD]) 0.38 (0.11)
PCI (n, %) 38 (29.9)
CABG (n, %) 21 (16.5)
DM type 1 (n, %) 2 (1.5)
DM type 2 (n, %) 20 (15.7)
Atrial fibrillation (n, %) 54 (42.5)
IHD (n, %) 66 (52.0)
COPD (n, %) 20 (15.7)
History of moking (n, %) 75 (59.1)
Enalapril (n, %) 99 (78.0)
Ramipril (n, %) 24 (18.9)
Trandolapril (n, %) 4 (3.1)
Beta-blockers (n, %) 110 (86.6)
Aldosterone inhibitors (n, %) 43 (38.9)
BMI: body mass index; BP: blood pressure; CABG: coronary artery bypass graft surgery; COPD: chronic
obstructive pulmonary disease; DM: diabetes mellitus;
EF: Left ventricular ejection fraction; IHD: ischemic heart disease; NYHA: New York Heart Association; PCI:
percutaneous coronary intervention; SD: standard deviation.
doi:10.1371/journal.pone.0163341.t001
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Influence of CES1 gene variations on the plasma ATII/ATI ratio
There were no statistical differences between the means of plasma ATII/ATI ratios from sub-
jects with any of the investigated CES1 variations when these were included either as three- or
two-level variables, respectively. Only rs2302722 (P = 0.27) complied with the pre-specified
limit (P<0.30) for further assessment in multivariate ANOVA models (Table 3). Mean plasma
ATII/ATI ratios among subjects with each of the three genotypes at rs2302722 and the loga-
rithmic-transformed values of the plasma ATII/ATI ratios used for the statistical analyses are
provided in Fig 3. As only two subjects were homozygous for the minor allele (T) at rs2302722,
the GT and TT genotypes were analyzed as a single group. In the fully adjusted analysis of the
effect of the rs2302722 genotype, the mean plasma ATII/ATI ratios for the GG genotype (LSM
Fig 1. Plasma angiotensin I (ATI) concentration and plasma ATII/ATI ratio after angiotensin-
converting enzyme inhibitor (ACEI) ingestion in patients with congestive heart failure after
completion of dose titration. Values are plotted against the time in hours from ACEI (enalapril, ramipril, or
trandolapril) ingestion until blood sample collection. Δ: Plasma ATII/ATI ratio, □: Plasma ATI concentrations.
doi:10.1371/journal.pone.0163341.g001
Table 2. CES1A1 variants: allele and genotype frequencies for the analyzed study population (n = 127).
SNP Position Reference allele Minor allele Major allele MAF Missing (n) Genotype (n/n/n) P-value (HWE)
rs3815583 Promoter T G T 0.20 7 8/32/80 0.068
rs12149373 Promoter A G A 0.23 7 15/24/81 0.000
rs12149371 Promoter A G A 0.19 7 9/28/83 0.007
rs12149322 Promoter G C G 0.21 7 11/28/81 0.001
rs12149370 Promoter A G A 0.18 7 5/34/83 0.556
rs12149368 Promoter C G C 0.14 7 6/22/92 0.007
rs111604615 Exon G C G 0.20 7 11/27/82 0.001
Rs566557773 Exon C T C 0.20 7 11/27/82 0.001
rs201577108 Exon T C T 0.20 7 11/27/82 0.001
rs12149366 Exon T G T 0.20 7 10/27/83 0.002
rs56278207 Intron - - T 0.33 9 18/42/58 0.034
rs71647871 Exon G A G 0.01 4 0/2/121 0.927
rs2302722 Intron G T G 0.10 41 2/13/71 0.160
rs2244614 Intron C C T 0.31 41 8/37/41 0.933
rs2244613 Intron C C A 0.04 41 0/7/79 0.694
SNP: single nucleotide polymorphism; MAF: minor allele frequency; HWE: Hardy-Weinberg equilibrium.
doi:10.1371/journal.pone.0163341.t002
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Table 3. Plasma angiotensin I (ATI) and ATII concentrations, and plasma ATII/ATI ratio.
Gene variation Genotype AT I (pg/ml; mean[SD]) AT II (pg/ml; mean[SD]) AT II/I-ratio (mean[SD]) P- Valuea P-Valueb
CES1A2 promoter - -
Weak 234.7 (31.2) 8.3 (8.6) 0.072 (0.134)
Strongc 59.1 (1.4) 4.2 (2) 0.071 (0.035)
- - -
Copy number 0.47 0.22
2 257.1 (258.3) 8.5 (8.3) 0.056 (0.049)
3 242.8 (354.6) 8.3 (6.9) 0.081 (0.133)
4 296.3 (383.7) 8.1 (2.4) 0.065 (0.044)
rs3815583 (T>G) 0.81 0.62
TT 233.0 (244.8) 8.3 (7.6) 0.067 (0.093)
TG 266.2 (353.5) 8.5 (9.2) 0.057 (0.044)
GG 290.6 (386.9) 7.7 (3.2) 0.066 (0.058)
rs71647871 (G>A) - -
GG 253.6 (289.2) 8.5 (7.9) 0.063 (0.08)
GA 171.4 (169.1) 8.5 (5.2) 0.068 (0.036)
AA - - -
rs2244613 (C>A) 0.42 -
AA 267.4 (66.5) 8.6 (8.5) 0.056 (0.051)
CA 119.9 (112.3) 6.6 (7.3) 0.054 (0.015)
CC - - -
rs2244614 (C>T) 0.64 0.39
TT 210.3 (188.4) 8.1 (7.7) 0.056 (0.055)
CT 261.9 (300.6) 8.6 (9.6) 0.056(0.047)
CC 258.3 (236.4) 9.3 (6.1) 0.06 (0.031)
rs12149373 (A>G) 0.09 0.23
AA 225.6 (242.2) 8 (7.5) 0.066 (0.091)
AG 329.7 (386.2) 9.5 (10.3) 0.044 (0.031)
GG 219.6 (311.8) 7.9 (3.8) 0.085 (0.07)
rs12149371 (A>G) 0.75 0.58
AA 224.8 (242.8) 8 (7.4) 0.066 (0.09)
AG 284.1 (365.4) 9.3 (9.7) 0.06 (0.054)
GG 225.6 (242.2) 7.7 (3.9) 0.059 (0.059)
rs12149322 (G>C) 0.49 0.63
GG 211.6 (227.3) 8 (7.5) 0.066 (0.091)
GC 317.1 (399.0) 9.5 (9.7) 0.052 (0.039)
CC 225.6 (242.2) 7.5 (3.6) 0.079 (0.077)
rs12149370 (A>G) 0.69 0.65
AA 225.6 (295.3) 8 (7.5) 0.066 (0.091)
AG 304.2 (377.9) 9.2 (8.9) 0.058 (0.051)
GG 172.5 (169.8) 6.9 (2.9) 0.073 (0.07)
rs12149368 (C>G) 0.80 0.88
CC 247.5 (295.3) 8.2 (7.5) 0.063 (0.086)
CG 214.4 (196.2) 9 (9.8) 0.07 (0.058)
GG 332.9 (421.3) 8 (3.7) 0.063 (0.068)
rs111604615 (G>C) 0.77 0.65
GG 233.4 (250.8) 8.1 (7.5) 0.065 (0.091)
GC 273.1 (356.8) 9.3 (9.8) 0.054 (0.038)
(Continued )
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Table 3. (Continued)
Gene variation Genotype AT I (pg/ml; mean[SD]) AT II (pg/ml; mean[SD]) AT II/I-ratio (mean[SD]) P- Valuea P-Valueb
CC 269.9 (353.9) 7.8 (3.9) 0.079 (0.078)
rs566557773 (C>T) 0.90 0.65
CC 233.4 (250.8) 8.1 (7.5) 0.065 (0.091)
CT 259.7 (356.4) 9.4 (9.8) 0.063 (0.053)
TT 310.3 (351.6) 7.5 (3.7) 0.058 (0.055)
rs201577108 (T>C) 0.90 0.86
TT 233.4 (250.8) 8.1 (7.5) 0.065 (0.091)
TC 256.7 (356.4) 9.4 (9.8) 0.063 (0.053)
CC 310.3 (351.6) 7.5 (3.7) 0.058 (0.055)
rs12149366 (T>G) 0.67 0.93
TT 237.7 (252.3) 8.1 (7.4) 0.065 (0.09)
TG 236.5 (352.2) 9.2 (9.9) 0.065 (0.052)
GG 336.7 (358.9) 7.9 (3.7) 0.055 (0.057)
rs56278207 (ins[T]) 0.78 0.62
TT 247.7 (311) 8.8 (7.9) 0.073 (0.105)
-T 244.2 (271.1) 8.6 (9) 0.06 (0.051)
— 210.3 (239.3) 6.1 (3.3) 0.05 (0.029)
rs2302722 (C>T) 0.27 0.10
GG 279.1 (274.2) 8.7 (8.9) 0.055 (0.052)
GT 122.5 (130.9) 5.5 (3) 0.065 (0.038)
TT 278.5 (125.9) 16.5 (9.2) 0.058 (0.007)
SD: standard deviation.
aGenetic variants included as three leveled variables.
bGenetic variants included as two leveled variables.
cActive promoter
doi:10.1371/journal.pone.0163341.t003
Fig 2. Linkage disequilibrium (LD) relationships between single nucleotide polymorphisms (SNPs)
of CES1A1. The top of the figure shows SNPs and the bottom of the figure shows LD relationships as well as
LD blocks of highly coupled variants. The strength of LD was determined by R2 statistics.
doi:10.1371/journal.pone.0163341.g002
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0.041 [95% confidence interval (CI) 0.031–0.055]) and the minor allele carriers, i.e., GT and
TT (LSM 0.059 [95% CI 0.037–0.096]) did not significantly differ from each other, with a rela-
tive difference in LSMs of 0.67 (95% CI 0.43–1.07; P = 0.10). In analyses restricted to only
include enalapril-treated patients that constituted the vast majority of our study population
(7 8%), the relative difference between LSMs for the GG (0.039 [95% CI 0.028–0.054]) and GT
(0.064 [95% CI 0.036–0.112]) remained non-significant after correction for multiple compari-
sons (0.60 [95% CI 0.37–0.98], P = 0.045). There were no enalapril-treated individuals who
were homozygous for the minor allele (TT) of rs2302722. Hence, this genotype was not repre-
sented in the latter analysis.
Discussion
In this study of patients with CHF that underwent dose titration with ACEIs that are activated
by CES1, we investigated the impact of a total of 17 selectedCES1 variations on the plasma
ATII/ATI ratio, a proximal pharmacodynamicmarker of ACEI activity. Genetic analysis con-
firmed a high level of LD between several of the investigated CES1 variations. Furthermore, we
found no significant association between the examined genotypes and the plasma ATII/ATI
ratio, when data were assessed in univariate unbalancedANOVA models. In the subsequent
multivariate analyses of the effect of rs2302722 (the only CES1 variant that qualified for final
analyses) and in models that exclusively included enalapril-treated patients, respectively,
Fig 3. Distribution of the plasma angiotensin II (ATII)/ATI ratios (A) and logarithmic-transformed ATII/
ATI ratios (B) according to CES1A1 rs2302722 genotypes.
doi:10.1371/journal.pone.0163341.g003
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results remained non-significant based on the Bonferroni-corrected significance level for mul-
tiple comparisons. To our knowledge, we are the first to investigate the impact of CES1 varia-
tion on a pharmacodynamic outcome parameter of ACEI treatment and althoughmore studies
are clearly warranted, the results suggest that the investigated variants in CES1 are unlikely to
be major determinants of ACEI efficacy.
Due to the pivotal role of CES1 in the hydrolytic activation of most ACEIs and an increased
focus on individually tailored cardiovascular treatment, pharmacogenetic research on the
importance of CES1 variation for the response to ACEI treatment, as well as studies of CES1-
mediated drug-drug interactions, has lately received increasing interest. Numerous variants
within the entire gene encodingCES1 have been reported of which some have been shown to
reduce or increaseCES1 transcription and CES1 activity [18, 19, 36]. However, as yet only very
few CES1 variants have been associated with altered pharmacokinetics of ACEIs and clinical
outcomes among ACEI-treated patients. The non-conservative single nucleotide substitution
variation at codon 143 in exon 4 of CES1A1 that results in a change of the nucleotide G to an
A (rs71647871) was associated with marked reduction of CES1 in vitro activity and complete
inhibition of the hydrolytic conversion of trandolapril to the active metabolite trandolaprilat
[13]. This variation has also been associated with reduced in vitro hydrolysis of other ACEI
prodrugs, i.e., enalapril, ramipril, perindopril, moexipril, and fosinopril [36, 37]. To our knowl-
edge, only the SNP -816 A>C at CES1A2 has been associated with a clinical outcome measure
in patients treated with ACEIs, i.e., a reduction of the antihypertensive effect of imidapril in a
relatively small (n = 105) study of Japanese patients with hypertension [38]. However, a subse-
quent study of Japanese cancer patients revealed the SNP -816 A>C to reside in CES1P1 and
being absent or rare in CES1A2, thus questioning the exact nature of the association with the
response to imidapril [20].
The HWE testing of several of the SNPs produced low P values which could reflect genotyp-
ing inaccuracies or non-random sampling of our study population. However, since the applied
genotyping procedure has been extensively validated in our laboratory without giving rise to
suspected co-amplification of undesiredDNA fragments, e.g., fragments of CES1P1 or mixed
reads in the Sanger sequencing chromatograms (data not shown), it is highly unlikely that geno-
typing inaccuracieswere primary determinants of these low P values. Instead, we focused our
attention on the potential pathophysiological functions of CES1. Besides having a role in the
hydrolytic conversion of various drugs, CES1 is involved in several endogenous physiological
processes, e.g., hydrolytic conversion of cholesteryl esters and triacylglycerol,[39–43] fatty acyl
coenzymeA hydrolysis,[44] and fatty acid ethyl ester synthase activity,[44, 45] and may there-
fore be implicated in development of cardiovascular disease, e.g. by contributing to dyslipidemia
associated with increased risk of ischaemic heart disease.[46] Accordingly, the low P values
observedupon HWE testing of several of the SNPs could reflect that patients with certainCES1
genotypes and CHF disease subtypes were preferentially recruited in the study. Also, the scien-
tific value of analyses of SNPs that are in strong LDmay be limited as these to some extent rep-
resent redundant analyses. However, due to the observedminor differences in MAFs between
the SNPs in the LD block, which are all solitarymarkers of the haplotype carryingCES1VAR,
we found it reasonable to report the results of all the included genetic variations. In the present
study, although the subanalysis of enalapril-treated patients produced a P value of 0.045, the
results of the fully adjusted models of rs2302722 did not reach sufficient levels of significance,
particularly not after Bonferroni correction for multiple parallel comparisons. Nonetheless,
rs2302722 represented the most promising pharmacogenetic variant of our current enquiry.
In the current study, we did not find any association betweenCES1 variants and the plasma
ATII/ATI ratio when all ACEIs were included in the model, and the results did not change
when genetic variants were condensed into dichotomous variables or in multivariate analyses
CES1 Gene Variants and ACEI Treatment
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where only enalapril-treated patients were included, respectively. These results are in line with a
recently published in vitro study that found no association betweenCES1 copy number variation
and CES1 activity, and where the nonsynonymous CES1 variants G19V, S83L and A270S had
no influence on ACEI activation by CES1 [36]. Conversely, our results may be contrary to previ-
ously published results on a significant effect of rs2244613 on dabigatran activation and bleed-
ing, and the association between rs3815583 and appetite reduction in patients treated with
methylphenidate, respectively [24, 25]. However, the potential impact of these two genetic varia-
tions on CES1 expression and CES1 hydrolytic activity towards ACEIs or other substrates is not
yet known, and such observed effectsmight reflect LD with causal genetic variants related to the
efficacy and safety of these drugs. Also, although the correlation between plasma ACE activity
and the systemic (plasma) ATII/ATI ratio is well documented, systemic activation of the renin-
angiotensin system does not necessarily reflect tissue specificACE activity, which is also depen-
dent on the disease etiology and other pathogenic mechanisms [28, 29, 47]. In this regard, a pre-
vious study has found that myocardial, but not systemic, pulmonary or renal ACE activities
were increased in a rodent model of CHF, and human cardiac ACE gene expression has been
shown to be increased among patients with CHF compared to persons with normal hearts [48,
49]. Intriguingly, there are also studies to suggest that tissue specific conversion of ATI to ATII
increases over time despite treatment with ACEIs, and that intracellular ATII synthesis as well
as the mediation of the more prolonged genomic effects of ATII, e.g., translation of growth fac-
tors and immunomodulatory cytokines, is independent of ACE activation and ATII receptor
type 1 binding, respectively [50, 51]. Furthermore, an aldosterone escape has been reported
in several studies with rising systemic levels of aldosterone during prolonged treatment with
ACEIs in patients with CHF [52]. Accordingly, the negative findings of the present study do not
allow for conclusions on effects of CES1 variations on specific effects of ACEIs.
Although the therapeutic actions of ACEIs are considered to represent a drug class effect,
the molecular structures of these drugs are distinct, which may affect their individual pharma-
cokinetic and pharmacodynamic properties [53, 54]. Also, the tissue penetration has been
shown to vary betweenACEIs as a consequence of their respective lipophilicity [55]. A previ-
ous in vitro study also suggested that the efficacy of CES1-mediated hydrolysis of enalapril was
inferior to that of ramipril and trandolapril, and that these drugs exhibited different types of
CES1 enzyme kinetics [14]. Likewise, another recent study of healthy volunteers showed a 20%
reduction of enalaprilat (the activated form of enalapril) concentration in subjects homozygous
for the minor allele at rs71647871, whereas no observable effect of this SNP was found on the
pharmacokinetics of quinapril [37]. Clopidogrel is also a substrate for CES1, and after ingestion
more than 90% of this prodrug is hydrolyzed to an inactive metabolite by hepatic CES1, thus
escaping cytochrome P450-mediated activation [23]. Importantly, in vitro studies have shown
that enalpril and trandolapril inhibited the CES1-mediated hydrolysis of clopidogrel to the
deesterified and inactive metabolite, which was translated into an increased risk of clinically
significant bleeding in patients with acute myocardial infarction co-treated with clopidogrel
and ACEIs [17]. However, these results have subsequently been challenged and the sum of cur-
rent evidencewould appear to indicate that although CES1 variation may account for some
variability of CES1 enzymatic activity between individuals, the frequency and the effect size of
the variants of CES1 are likely to be small. Hence, these variants may have limited clinical rele-
vance [56].
Strengths and limitations
The present study was restricted by a relatively small sample size and hence had limited statisti-
cal power. Consequently, we were unable to do analyses stratified for individual ACEIs and
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ACEI doses, respectively. However, we found no significant differences in maintenance doses
of enalapril (the most frequently used ACEI) between the investigated CES1 variants (not
shown). In addition, low P values were obtained by HWE testing of several SNPs which com-
plicated the interpretation of some of the findings. In contrast to previous studies on plasma
ATI and ATII levels in ACEI-treated patients, where subjects rested in a supine position before
blood samples were collected, we applied a sitting position that may have influencedAT levels
[57]. However, the plasma ATII/ATI ratio and the relationship between this ratio and circulat-
ing levels of ATI during ACEI treatment observed in the present study were comparable to
previous findings [29, 58]. Also, environmental factors may have affected the impact of CES1
variants and ACEI treatment on the plasma ATII/ATI ratio, including dietary habits, and
results might have been influenced by CES1-dependent interactions with endogenous CES1
substrates and other CES1-metaboliseddrugs often used for patients with CHF, e.g., simva-
statin and carvedilol [59–62]. Furthermore, patients with CHF frequently have altered drug
pharmacokinetics owing to, e.g., intestinal congestion, reduced organ perfusion, and impaired
renal and hepatic drug clearance, which also may have affected the results [63]. Also, as the
current study did not examine all known genetic variants of CES1, we cannot exclude the possi-
bility that undeterminedCES1 variants may have contributed to the variability in ACEI pro-
drug activation and subsequent pharmacodynamics.
Conclusion
The present study of patients with CHF that underwent ACEI dose titration did not support an
association between a range of CES1 variants and ACEI pharmacodynamicsmeasured by the
plasma ATII/ATI ratio. These findings indicate that the investigated variants in CES1 are
unlikely to be primary determinants of ACEI efficacy.
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